PTX-200 and Carboplatin in Ovarian Cancer

Inclusion Criteria:

At least 18 years of age
Histologically confirmed, measurable or non-measurable, recurrent or persistent, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma. By standard Gynecologic Oncology Group (GOG) criteria, platinum-resistant disease is defined by a disease-free interval of less than 6 months following treatment with a platinum-based regimen, or the progression of disease during platinum-based therapy.
At least one prior regimen of chemotherapy, with no maximum number of chemotherapy cycles
A serum creatinine ≤ 1.5 mg% obtained ≤ 2 weeks prior to entry
Adequate hematologic reserve obtained ≤ 2 weeks prior to entry: leukocytes ≥ 3,000 mm^3; absolute neutrophil count ≥ 1500 mm^3; platelets ≥ 100,000 mm^3
Adequate hepatocellular function: aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤ 3x upper limit of normal within institutional limits; bilirubin ≤ 1.5 mg/dl
Gynecologic Oncology Group (GOG) Performance Status of 0, 1, or 2
Life expectancy of at least 90 days
The patient should be off chemotherapy, biologic therapy and radiation for 28 days.
Neuropathy (sensory and motor) less than or equal to grade 1 per Common Toxicity Criteria (CTC) version 4

Exclusion Criteria:

Prior TCN-PM therapy
History of allergic reactions attributed to compounds of similar chemical or biologic composition to TCN-PM
Patients must be disease-free of prior invasive malignancies for >2 years with the exception of basal cell or squamous cell carcinoma of the skin.
Inability to give informed consent
Pregnancy
Corrected QT interval (QTc) prolongation > 450 milliseconds (msec)